

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Kiu Hung International Holdings Limited**

**僑雄國際控股有限公司**

*(incorporated in the Cayman Islands with limited liability and continued in Bermuda with limited liability)*

**(Stock Code: 00381)**

### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

#### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

The board of directors of the Company is pleased to announce that Mr. Hou Yunde (“**Academician Hou**”) has been appointed as the independent non-executive director with effect from 27 October 2020. He also has been appointed as the non-executive chairman of the board of directors with effect from 27 October 2020.

The biographical details of Academician Hou are as follows:

Mr. Hou Yunde (侯雲德) served as the deputy president of the Chinese Academy of Engineering and the director of the Institute of Virology, Chinese Academy of Preventive Medicine. He is currently the chief technical engineer of the Special Science Research Project on “Control and Prevention of AIDS, Virus Hepatitis, and other Serious Infectious Diseases” in China.

On 8 January 2018, Xi Jinping, as the General Secretary of the Central Committee of the Communist Party of China, the PRC President and the Chairman of the Central Military Commission, conferred the 2017 Highest Science and Technology Award on Academician Hou Yunde, in recognition that “He is not only the pathfinder of China’s genetic engineering drugs, but also the forerunner of China’s modern pharmaceutical biotechnology industry. Furthermore, he is the chief designer of China’s modern integrated prevention and control technology system for infectious diseases”.

Academician Hou Yunde is an outstanding strategic scientist and technology scholar in the field of biomedicine in China. Besides being a molecular pathologist, he is also a major founder of modern pharmaceutical biotechnology industry and modern prevention and control technology system for infectious diseases in China.

Academician Hou Yunde, who has made outstanding contributions to the establishment of modern prevention and control technology system for infectious diseases in China, led the expert team to design the overall plan for China to respond to major outbreaks of epidemics

and reduce the “three diseases and two rates” from 2008 to 2020 at the top level, enabling China to successfully cope with a number of severe infectious diseases that have occurred at home and abroad in the past decade. In 2009, faced with the global outbreak of H1N1 pandemic, Hou Yunde led the expert team to develop a new influenza A vaccine in only 87 days. As a result, China became the first country in the world to approve the marketing of influenza A vaccine, which set a precedent for the first successful intervention in the pandemic in the history of mankind. Hou Yunde won the first prize of the 2014 National Prize for Progress in Science and Technology.

Academician Hou Yunde has successfully developed China’s first genetically-engineered pharmaceuticals and a series of bioengineering pharmaceuticals. A variety of genetically-engineered pharmaceuticals developed by him have been transferred to over a dozen domestic pharmaceutical companies. He is the founder of biogenetic engineering pharmaceuticals in China and the leader in the transformation of biotechnology achievement. Currently, Hou Yunde also serves as an expert consultant in A-share listed companies such as Kangtai Biological (300601) and Zhifei Biological (300122).

The Company attaches great importance to the appointment of Academician Hou, and it will take this opportunity to give full play to the advantages of the Company and strive to seek new business opportunities in genetic engineering, vaccines and bio-pharmaceuticals in order to maximize the shareholder value for investors.

There is no service agreement entered into between the Company and Academician Hou. Academician Hou has been appointed for a term of two years, subject to retirement by rotation and re-election pursuant to the articles of association of the Company. Academician Hou is entitled to an annual emolument of HK\$120,000. The remuneration of Academician Hou was determined by the Board with the recommendation of the remuneration committee of the Company after considering a range of factors including the prevailing market conditions, director’s duties and responsibilities in the Group and performance and results of the Group.

As at the date of this announcement, (i) Academician Hou does not hold any position in the Company or any of its subsidiaries nor have any relationship with any Director, senior management or substantial or controlling shareholders of the Company; (ii) Academician Hou has not held any directorship in other public companies, which are listed on any securities market in Hong Kong or overseas in the past three years or other major appointments and professional qualifications; (iii) Academician Hou has or is deemed to have no interest and short positions in any Shares, underlying shares and debentures of the Company or any of its associated corporation which is required to be disclosed under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed herein, there is no other information relating to the appointment of Academician Hou that needs to be brought to the attention of the shareholders of the Company nor is there any information relating to Academician Hou which is required to be disclosed pursuant to Rules 13.51(2)(h) to (2)(v) of the Listing Rules.

The board of directors would like to take this opportunity to welcome Academician Hou for joining the Company.

By order of the Board  
**Kiu Hung International Holdings Limited**  
**Zhang Qijun**  
*Chairman*

Hong Kong, 27 October 2020

*As at the date of this announcement, the Board comprises three executive Directors, Mr. Zhang Qijun, Mr. Chen Jian and Mr. Liu Mingqing and five independent non-executive Directors, Mr. Wang Xiao Ning, Mr. Cheng Ho On, Mr. Kong Chun Wing, Mr. Lai Chi Yin, Samuel and Ms. Chen Yuxin.*